Sunday, May 09, 2021 3:27:26 AM
" They will not release TLD at a virtual conference."
I agree, at least not full in depth data, but possibly a quick summary.
I'm trying to look at this logically, although I am not a business major or work in financial field.
I am thinking partnership. reasons:
LP remains in control for as long as she wants of NWBO
LP possibly on board of directors of partner.
Instant financing
possible help in moving to NYSE
Legal help
New hires are protected
More access to candidates for future trials
quicker rollout of product
Help with FDA and other regulatory bodies
Instant stock increase. Dividends for the boards retirement years
They can go it alone and have everything set to do so, but for the above reasons i think partnership. Helping the most people as quickly as possible.To roll this out to the world, they need help.
If Merck, a partnership offers trials of combinations of treatments. Shared data, It also protects DCvax from not getting lost in the BP world.
I added 5000 more shares friday.
just my 2 cents.
I agree, at least not full in depth data, but possibly a quick summary.
I'm trying to look at this logically, although I am not a business major or work in financial field.
I am thinking partnership. reasons:
LP remains in control for as long as she wants of NWBO
LP possibly on board of directors of partner.
Instant financing
possible help in moving to NYSE
Legal help
New hires are protected
More access to candidates for future trials
quicker rollout of product
Help with FDA and other regulatory bodies
Instant stock increase. Dividends for the boards retirement years
They can go it alone and have everything set to do so, but for the above reasons i think partnership. Helping the most people as quickly as possible.To roll this out to the world, they need help.
If Merck, a partnership offers trials of combinations of treatments. Shared data, It also protects DCvax from not getting lost in the BP world.
I added 5000 more shares friday.
just my 2 cents.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
